Press Releases 2013

Contact Us Today!

617-523-7900

or Use Our Simple Online Form to Give Us Feedback

We welcome your comments and feedback. Please include contact information if you'd like a response.

Did you find this page helpful?





If you would like a response, please include your contact information.

Lessons Learned from the First Successful Gene Therapy for Blinding Retinal Disorders

Contact:
Mary Leach, 617-573-4170

Boston, Mass. (March 25, 2013) -- Follow-up results from one of several groundbreaking gene therapy studies reported in 2008 in patients with an inherited form of retinal blindness confirmed the earlier positive results of substantial improvement in vision that has now persisted for more than four years. However, the new study* also showed that while gene therapy was able to improve patients' vision, it did not slow or stop the underlying disease process.

The implications of these new findings for the future of this promising area of gene therapy are explored in an insightful Commentary in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The Commentary is available on the Human Gene Therapy website.

Drs. Connie Cepko and Luk Vandenberghe, Department of Ophthalmology, Harvard Medical School, Boston, MA, describe the promising follow-up study results recently reported by Cideciyan et al., and published in PNAS,  as well as the "sobering data" that indicate continuing disease progression. The replacement gene delivered into the affected retina was able to supplement the dysfunctional photoreceptors in the patients' eyes, yet it did not affect the degenerative process destroying the photoreceptor cell layer.

In the Commentary "Retinal Gene Therapy Coming of Age," the authors discuss ways in which the therapeutic approach could be refined, combined with other forms of treatment, initiated earlier in the course of the disease, or otherwise improved to achieve a more complete therapeutic outcome.

 “The paper published in PNAS and the associated commentary published in Human Gene Therapy provided important context for the long-term follow-up of the pioneering gene therapy performed in patients with LCA2,” says James M. Wilson, M.D., Ph.D., Editor-in-Chief, and Director of the Gene Therapy Program, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia. "What is surprising is that there appears to be some degeneration of photoreceptors despite the durable improvement in sight. What this means in terms of longer term efficacy is unclear. What is absolutely clear is that this patient cohort benefited from the gene therapy, and after many years they still benefit.”

 *CIDECIYAN AV, JACOBSON SG, BELTRAN WA, SUMAROKA A, et al. (2013). Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement. Proceedings of the National Academy of Sciences of the United States of America 110, E517-25.

(Information for this release provided by Mary Ann Liebert Publishing)